{Etokimab: A Deep Investigation into the 2022981-44-6 Protein Etokimab, designated by the distinct identifier 2022981-44-6, represents a groundbreaking immunoglobulin currently subject to clinical evaluation. This https://www.targetmol.com/compound/etokimab